HTG Announces Recipients of Its 2020 HTG EdgeSeq Autoimmune Panel Research Grants
Dr. Dörner was awarded the grant for his research, Alterations of key immune pathways in distinct B-cell subsets of patients with systemic lupus erythematosus (SLE), which is intended to identify key pathways and possible biomarkers and therapeutic targets in different B-cell subsets, ultimately helping to refine the understanding of the role and relevance of different B-cell populations in SLE patients.
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Safe Harbor Statement
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the work of the researchers named in this press release leading to important advancement in autoimmune disorders and potential future peer-reviewed publications. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including but not limited to, the ability of our technology to enable scientists to offer more effective diagnosis and treatment options to individuals impacted by autoimmune disorders and the risk that our technology does not perform as expected. These and other factors are described in greater detail in our filings with the
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.